INBX Stock Forecast & Price Target

Inhibrx Biosciences Inc. is positioned favorably due to its strong cash position of $152.6 million, which enables the continued development of its promising therapeutic candidates, INBRX-109 and INBRX-106. The company's proprietary single-domain antibody and protein engineering platforms offer significant mid-to-long-term growth potential, particularly as clinical readouts are anticipated in the third and fourth quarters of 2025. Despite reporting an EPS of ($3.09) for Q4 2024, the expected cash reserves by the end of 2025 indicate a potential valuation of $4.66 per share, reflecting an attractive investment opportunity.

Inhibrx Biosciences Inc. reported $100K in revenues for 4Q24, which raises concerns as it significantly trails behind the substantial R&D expenses of $33.4MM, reflecting a potential imbalance in financial health. The company faces substantial risks, including the possibility of delays in regulatory approvals, competition from other drugs, and lack of distinguishing clinical data, all of which could adversely impact future sales potential and share price performance. Additionally, the higher-than-expected SGA expenses of $16.7MM further complicate its financial outlook amid the inherent risks of clinical trial failures associated with its two therapeutic candidates.